Everolimus with exemestane in elderly breast cancer patients – case report

• Authors: Agnieszka Jagiełło-Gruszfeld
• Languages of publication: EN

Abstracts

EN

Treating elderly patients suffering from metastatic breast cancer still constitutes a significant therapeutic problem. The possibility of administering everolimus in combination with exemestane appears to be a promising therapeutic option in the case of hormone-dependent cancers, without HER2 receptor overexpression.

Keywords

EN

breast cancer; elderly; everolimus; exemestan

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2014
• Volume: 4
• Issue: 1
• Pages: A33-36

Contributors

author

Agnieszka Jagiełło-Gruszfeld

• Clinic I, Maria Sklodowska-Curie Institute of Oncology, Warsaw

References

• Didkowska J, Wojciechowska U, Zatoński W. Malignant tumours in Poland in 2011. National Cancer Registry.
• Pritchard KI, Gelmon KA, Rayson D et al. Endocrine therapy for postmenopausal women with hormone receptor-positive HER2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol.
• Baselga J, Campone M, Piccart M et al. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2012; 366: 520-9.
• Paplomata E, Zelnak A, O’Regan R. Ewerolimus: side effect profile and management of toxicities in breast cancer. Future Oncol. 2012; 8(6): 651-657.
• Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol. 2012; 8(6): 651-7
• Pritchard KI, Burris HA 3rd, Ito Y et al. Safety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 2013; 13(6): 421-432.e8.

• Document Type: report